Candel Therapeutics Option Alert: Fri $7 Calls Sweep (3) near the Ask: 1440 vs 1720 OI; Earnings 3/27 Before Open [est] 

Candel Therapeutics Option Alert: Fri $7 Calls Sweep (3) near the Ask: 1440 @ $5.2 vs 1720 OI; Earnings 3/27 Before Open [est] Ref=$12.21

Candel Therapeutics 주식 (NASDAQ: CADL)

Candel Therapeutics (NASDAQ:CADL) 주식

Candel Therapeutics

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Equities

News

Markets

ADBE

CADL

TSLA

수요일(11일) 미국 증시는 최근의 인플레이션 보고서에 힘입어 낙관적인 분위기를 보였다. 나스닥 100 지수는 1.7% 급등하여 새로운 최고치를 기록했고, S&amp;P 500 지수는 0.8% 상승했다. 게임스탑, 어도비, 메타, 캔델 테라퓨틱스 및 테슬라

수요일 주목받은 주식: 게임스탑, 어도비, 메타, 캔델 테라퓨틱스 및 테슬라

NVDA

PLTR

미국 주식 시장은 목요일에 하락하며, 다우존스 지수는 1.35% 하락한 38,596.98에 도달했다. NASDAQ와 S&amp;P 500도 각각 1.4% 하락한 16,049.08과 1.23% 하락한 5,147.21을 기록했다. 전체 시장의 하락에도 불구하고, 일부 종목은 소매 트레이더와 투자자들의 주목을 끌었다.



하루 내내 소매 트레이더와 투자자들의 관심을 끌은 주요 주식은 다음과

목요일의 주요 주식: 포드, 캔들 테라퓨틱스, 엔비디아, 팔란티어, 테슬라

Candel Therapeutics Inc

Cadeler AS

<h3>Companies Reporting Before The Bell</h3>
• 908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) is likely to report quarterly loss at $0.37 per share on revenue of $16.18 million. 
• Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) is projected to report quarterly loss at $0.23 per share on revenue of $262.65 million. 
• NexGen Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXE#NYSE">NXE</a>) is projected to report earnings for its fourth quarter. 
• EVgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $69.00 million. 
• L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $131.48 million. 
• WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $25.59 million. 
• InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $34.40 million. 
• Amylyx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) is expected to report earnings for its fourth quarter. 
• Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) is projected to report quarterly loss at $0.24 per share on revenue of $18.98 million. 
• Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $26.94 million. 
• Olaplex Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $87.51 million. 
• Hagerty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $279.58 million. 
• Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $9.99 million. 
• Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $63.06 million. 
• Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) is expected to report quarterly loss at $0.15 per share on revenue of $17.71 million. 
• Paysafe (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>) is projected to report quarterly earnings at $0.72 per share on revenue of $437.22 million. 
• Compugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEN#NASDAQ">CGEN</a>) is likely to report quarterly loss at $0.07 per share on revenue of $24.96 million. 
• Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) is expected to report quarterly earnings at $0.70 per share on revenue of $4.60 billion. 
• Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $175.71 million. 
• On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $593.34 million. 
• Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $91.89 million. 
• Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) is likely to report quarterly earnings at $2.42 per share on revenue of $13.69 billion. 
• Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) is likely to report quarterly earnings at $2.65 per share on revenue of $30.28 billion. 
• CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) is estimated to report quarterly earnings at $0.57 per share on revenue of $118.97 million. 
• Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $290.88 million. 
• Modiv Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDV#NYSE">MDV</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $11.86 million. 
• AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) is estimated to report quarterly earnings at $29.90 per share on revenue of $4.00 billion. 
<h3>Companies Reporting After The Bell</h3>
• Medallion Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFIN#NASDAQ">MFIN</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $53.66 million. 
• Southland Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SLND#AMEX">SLND</a>) is projected to report quarterly loss at $0.49 per share on revenue of $230.13 million. 
• Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $41.00 million. 
• Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) is projected to report earnings for its fourth quarter. 
• Baytex Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTE#NYSE">BTE</a>) is estimated to report quarterly earnings at $0.16 per share on revenue of $980.40 million. 
• Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) is estimated to report quarterly earnings at $0.39 per share on revenue of $26.54 million. 
• ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $26.52 million. 
• Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $57.60 million. 
• Astronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRO#NASDAQ">ATRO</a>) is likely to report quarterly earnings at $0.28 per share on revenue of $194.91 million. 
• Fuel Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEK#NASDAQ">FTEK</a>) is expected to report quarterly loss at $0.03 per share on revenue of $5.63 million. 
• comScore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $91.66 million. 
• Alpha Teknova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $8.78 million. 
• Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) is projected to report quarterly loss at $0.08 per share on revenue of $124.13 million. 
• NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $21.11 million. 
• ATN International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNI#NASDAQ">ATNI</a>) is projected to report quarterly loss at $0.19 per share on revenue of $179.11 million. 
• Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) is projected to report quarterly loss at $0.16 per share on revenue of $49.37 million. 
• OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) is projected to report quarterly loss at $0.26 per share on revenue of $52.70 million. 
• Ascent Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNT#NASDAQ">ACNT</a>) is expected to report earnings for its fourth quarter. 
• Ecopetrol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $7.68 billion. 
• Horizon Tech Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRZN#NASDAQ">HRZN</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $25.68 million. 
• Owlet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWLT#NYSE">OWLT</a>) is expected to report quarterly loss at $0.48 per share on revenue of $16.92 million. 
• AeroVironment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) is expected to report quarterly earnings at $0.86 per share on revenue of $214.00 million. 
• Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) is estimated to report quarterly earnings at $1.67 per share on revenue of $5.95 billion. 
• Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $77.23 million. 
• Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) is expected to report quarterly loss at $0.20 per share on revenue of $6.23 million. 
• CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) is expected to report quarterly loss at $0.31 per share on revenue of $58.79 million. 
• Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) is likely to report quarterly earnings at $0.90 per share on revenue of $13.22 billion. 
• ChargePoint Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) is likely to report quarterly loss at $0.07 per share on revenue of $100.97 million. 
• Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) is estimated to report quarterly earnings at $0.18 per share on revenue of $120.31 million. 
• Crexendo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXDO#NASDAQ">CXDO</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $15.64 million. 
• CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is estimated to report quarterly earnings at $0.86 per share on revenue of $1.03 billion. 
• Ooma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OOMA#NYSE">OOMA</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $64.70 million. 
• Custom Truck One Source (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTOS#NYSE">CTOS</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $539.81 million. 
• Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $214.41 million. 
• Orion Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) is estimated to report quarterly earnings at $0.19 per share on revenue of $272.70 million. 
• Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $84.95 million. 
• Box (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $278.60 million. 
• Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is projected to report quarterly earnings at $0.91 per share on revenue of $223.23 million. 
• Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) is projected to report earnings for its fourth quarter. 
• Sociedad Quimica Y Minera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) is likely to report quarterly earnings at $0.84 per share on revenue of $1.13 billion. 
• Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) is likely to report quarterly earnings at $0.90 per share on revenue of $4.33 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

ACNT

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AOMR

ATNI

ATRO

AVAV

CDXC

CGEN

CHPT

CPIX

CRCT

CRDO

CRWD

CTOS

CXDO

CYRX

EOLS

EOSE

ESPR

EVGO

FSTR

FTEK

GENI

GIFI

HGTY

HRZN

INFU

INGM

KIDS

MASS

MFIN

NPCE

Nuveen Arizona Dividend Advantage Municipal Funds 3

NYAX

OLPX

ONON

OOMA

OWLT

PLUG

PMTS

PSFE

RIGL

ROST

SCOR

SLND

SOPH

STEM

STIM

SWIM

TKNO

WEYS

YMAB

Earnings Scheduled For March 4, 2025

CEVA

Ceva Partners With Arm And SynaXG To Offer A Customized 5G-Advanced Solution For 5G NR Processing In Wireless Network Equipment And Satellites

President Donald Trump directed a pause to U.S. military aid to Ukraine on Monday, pressuring Ukrainian President Volodymyr Zelenskyy to engage in peace negotiations with Russia amid escalating <a href="https://in.benzinga.com/markets/eurozone/25/03/44083726/european-leaders-support-zelenskyy-deepening-ukraine-divide-with-us">tensions between the two leaders</a>.
What Happened: The White House confirmed the aid freeze will remain until Trump determines Ukraine has demonstrated commitment to peace talks with Russia. A White House official <a href="https://apnews.com/article/trump-zelenskyy-russia-ukraine-a15a459c9a3a393d040478ebbe250a9e">told</a> the Associated Press on condition of anonymity described the move as &#8220;pausing and reviewing&#8221; assistance to &#8220;ensure that it is contributing to a solution.&#8221;
The decision follows a contentious Oval Office meeting where Trump and Vice President JD Vance criticized Zelenskyy over what they perceived as insufficient gratitude for the more than $180 billion in U.S. military aid provided to Kyiv since Russia&#8217;s invasion.
Trump has grown increasingly frustrated with Zelenskyy, particularly after the Ukrainian leader suggested Sunday that an end to the war &#8220;is still very, very far away.&#8221; Trump responded sharply on Truth Social: &#8220;This is the worst statement that could have been made by Zelenskyy, and America will not put up with it for much longer!&#8221;
<figure class="wp-block-image aligncenter size-full is-resized"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04023252/Screenshot-2025-03-04-at-1.02.09%E2%80%AFPM.png" alt="" class="wp-image-807385" style="width:685px;height:auto" /></figure>
See Also:&nbsp;<a href="https://www.benzinga.com/personal-finance/25/03/44068159/nba-legend-shaq-says-his-net-worth-quadrupled-once-he-took-note-from-jeff-bezos-and-started-investing-in-things-that-change-peoples-lives" target="_blank" rel="noreferrer noopener">NBA Legend Shaq Says His Net Worth ‘Quadrupled&#8217; Once He Took Note From Jeff Bezos And Started Investing In Things That ‘Change People&#8217;s Lives&#8217;</a>
Why It Matters: European leaders have <a href="https://in.benzinga.com/markets/eurozone/25/03/44083726/european-leaders-support-zelenskyy-deepening-ukraine-divide-with-us">rallied behind Zelenskyy</a>, with British Prime Minister Keir Starmer pledging a £2.26 billion loan for military supplies backed by profits from frozen Russian assets. This growing divide between U.S. and European approaches to Ukraine creates uncertainty for investors in transatlantic defense partnerships.
A minerals deal that would have given the U.S. access to Ukraine&#8217;s critical minerals resources as partial repayment for aid was expected to be signed during Zelenskyy&#8217;s visit. Rep. Brian Fitzpatrick (R-PA), co-chair of the Congressional Ukraine Caucus, has spoken with Zelenskyy&#8217;s chief of staff about reviving this economically significant agreement.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I just had a lengthy and productive one-on-one conversation with President Volodymyr Zelenskyy's Chief-of-Staff, Andrii Yermak. We are 100% getting this train back on the tracks. This mineral deal will be signed in short order, which will lead to a strong long-term economic…
&mdash; Rep. Brian Fitzpatrick &#x1f1fa;&#x1f1f8; (@RepBrianFitz) <a href="https://twitter.com/RepBrianFitz/status/1896663350370566156?ref_src=twsrc%5Etfw">March 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/03/44065932/mark-cuban-was-asked-how-hed-invest-100k-his-answer-buy-bulk-toothpaste-and-soup-for-the-best-guaranteed-return-on-investment" target="_blank" rel="noreferrer noopener">Mark Cuban Was Asked How He&#8217;d Invest $100K — His Answer? Buy Bulk Toothpaste And Soup For The ‘Best Guaranteed Return On Investment&#8217;</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Politics

Global

Trump Reportedly Halts Ukraine Military Aid, Pressures Zelenskyy To Seek Peace With Russia Amid Growing Rift

An investor who shorted Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)&nbsp;with massive leverage is now&nbsp;sitting on tens of millions in unrealized profit&nbsp;as the market plunged following President Donald Trump&#8217;s tariff announcement.
What Happened: The trader took a 50x leverage bet on ETH&#8217;s decline on Monday, according to on-chain tracker Lookonchain. 
As the second-largest cryptocurrency fell after Trump confirmed plans to impose tariffs on key trade partners like Canada, Mexico, and China, the trader&#8217;s unrealized gains rocketed up to a whopping $81 million. As of this writing, the trader had already begun closing part of the short positions to secure profits. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">As <a href="https://twitter.com/search?q=%24ETH&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ETH</a> drops, the whale who shorted <a href="https://twitter.com/search?q=%24ETH&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ETH</a> with 50x leverage is now sitting on an unrealized profit of over $81M! The whale has already started closing part of short positions to lock in profits.<a href="https://t.co/8utezkrdPy">https://t.co/8utezkrdPy</a> <a href="https://t.co/edRVWAnQzf">pic.twitter.com/edRVWAnQzf</a>
&mdash; Lookonchain (@lookonchain) <a href="https://twitter.com/lookonchain/status/1896761748759420992?ref_src=twsrc%5Etfw">March 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Interestingly, this development follows a 50x long trade by a whale on Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum, turning a $4 million investment into a $200 million position. The trader closed their position shortly before Trump announced a&nbsp;<a href="https://www.benzinga.com/25/03/44068814/bitcoin-ethereum-dogecoin-rally-on-trumps-strategic-crypto-reserve-announcement-cardano-xrp-solana-skyrocket-analyst-says-btcs-new-ath-possible-later-in-the-month" target="_blank" rel="noreferrer noopener">cryptocurrency reserve</a>, resulting in a profit of over $6 million.
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44069015/bitcoin-is-digital-gold-but-whats-the-rationale-for-an-xrp-reserve-asks-peter-schiff-cardano-founder-charles-hoskinson-says-trump-made-the-right-decision">Bitcoin Is Digital Gold But &#8216;What&#8217;s The Rationale For An XRP Reserve&#8217;, Asks Peter Schiff: Cardano Founder Charles Hoskinson Says Trump Made The Right Decision</a>
Benzinga Note:&nbsp;Leverage trading allows cryptocurrency traders to open larger positions using borrowed capital. While it can potentially amplify profits, it also significantly increases the risk of substantial losses due to the volatile nature of the cryptocurrencies.
Why It Matters: The timing of these trades has sparked speculation of possible insider trading. Panos, an X user, wondered if the long-leveraged trade before the cryptocurrency reserve-fueled rally and the bearish bets before the tariff-induced dump were coincidental or deliberate.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">First someone opens a multi million dollar 50x long right before Trump announces what coins will be part of the crypto strategic reserve Then someone opens 50x short the next day. Totally not insiders. <a href="https://t.co/4Akm5Lti62">https://t.co/4Akm5Lti62</a>
&mdash; Panos (@stridentcitizen) <a href="https://twitter.com/stridentcitizen/status/1896763911426433206?ref_src=twsrc%5Etfw">March 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Earlier in the day, renowned economist Peter Schiff<a href="https://in.benzinga.com/25/03/44100165/peter-schiff-anthony-scaramucci-question-trumps-crypto-reserve-announcements-seek-congressional-inquiry"> sought investigation</a> into Trump&#8217;s cryptocurrency announcements, with details on how much those with "advance notice" spent on the cryptocurrencies included in the reserve, as well as how much profit they made selling them.
Notably, on-chain sleuth and Coinbase executive Conor Grogan <a href="https://in.benzinga.com/25/03/44069726/big-gamble-or-insider-tradingwhale-opens-50x-leveraged-long-position-on-bitcoin-etherum-closes-just-before-trumps-crypto-reserve-announcement">found out</a> that the trader related to the 50x long leverage trade was a casino gambler, known for executive high-leveraged trades, and not someone privy to insider info.
Price Action: At the time of writing, Ethereum was exchanging hands at $2,077.37, down 12.81% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/03/44069228/elon-musk-labels-meme-coins-as-casino-like-dont-sink-your-life-savings">Elon Musk Labels Meme Coins Casino-Like: Tesla CEO Says &#8216;Don&#8217;t Sink Your Life Savings&#8217; Even As Dogecoin Pumps Over 10%</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Whale Leveraged 50x Short Sees $81 Million In Paper Gains As Ethereum Plummets After Trump's Tariff Confirmation

Tencent Holdings' (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCEHY#OTC">TCEHY</a>) Yuanbao AI chatbot has surpassed DeepSeek as the most downloaded iPhone app in China.
What Happened: Tencent integrated its in-house Hunyuan AI technology with DeepSeek's R1 reasoning model, boosting the chatbot's appeal and helping it claim the No. 1 spot on China's iPhone app rankings this week, according <a href="https://www.bloomberg.com/news/articles/2025-03-04/tencent-s-ai-bot-passes-deepseek-as-china-s-favorite-on-iphones">to</a> a report by Bloomberg.
DeepSeek had dominated downloads for over a month. Three of the top five free apps in China are now AI-powered chatbots, with ByteDance's Doubao also ranking among them.
See Also: <a href="https://www.benzinga.com/25/03/44070969/former-intel-ceo-craig-barrett-warns-that-splitting-the-company-would-be-a-costly-mistake-a-far-better-move-might-be-to-fire-the-intel-board-and-rehire-pat-gelsinger">&#8216;Fire The Intel Board,&#8217; Says Former CEO Craig Barrett As He Pushes Back On Breakup Plans, Urges Focus On Chipmaking Wins</a>
In January, DeepSeek shook the U.S. stock market. Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) lost <a href="https://www.benzinga.com/markets/emerging-markets/25/01/43260751/not-just-deepseek-alibaba-unveils-ai-model-to-rival-openais-operator">$600 billion in value</a> in a single day.
According to the Chinese startup, its chatbot can compete with OpenAI&#8217;s ChatGPT, which it developed at a fraction of the cost.
In <a href="https://in.benzinga.com/25/02/43970279/alibaba-and-deepseek-intensify-ai-showdown-challenging-openai-and-nvidias-market-dominance">response to DeepSeek's rise</a>, Alibaba Group Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) has begun benchmarking against it and announced a $53 billion AI investment.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It&#8217;s Important: China's leading tech giants—Tencent, Alibaba, and Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>)—are in a fierce race to capture the growing AI market.&nbsp;
While monetization strategies remain unclear, companies are focused on mass adoption and open-source AI development.
With its 1.4 billion WeChat users, Tencent has an advantage in distributing AI-powered services, but Alibaba and Baidu are making larger AI investments.&nbsp;
Meanwhile, Nvidia CEO Jensen Huang has spoken about the need for significantly more <a href="https://in.benzinga.com/markets/equities/25/02/43995515/jensen-huang-says-deepseek-was-fantastic-next-gen-models-demand-100x-more-compute-as-nvidia-smashes-earnings-records">computational power</a> for next-generation AI models.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/02/44055314/mrbeast-lost-millions-on-amazons-beast-games-now-hes-looking-to-raise-hundreds-of-millions-to-take-h" target="_blank" rel="noreferrer noopener">MrBeast Lost Millions On Amazon&#8217;s ‘Beast Games&#8217;—Now He&#8217;s Looking To Raise Hundreds Of Millions To Take His Brand To The Next Level</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Tech

Media

BABA

BIDU

TCEHY

DeepSeek Loses Top Spot As Tencent's Yuanbao AI Becomes The Top iPhone App In China Amid Intensifying AI Battle

The parties will further develop APIs to enable developers to create new applications for enterprises, including financial services and healthcare.

Proximus Global And Nokia Collaborate To Bring Advanced Network APIs To Developers For Enterprise Innovation

The collaboration also represents a significant step forward in revolutionizing how businesses use AI and network APIs to enhance operations and customer experiences. SAP provides the foundational platform, integrating SAP Business AI with SAP BTP. Vonage helps to elevate these capabilities with communications and network APIs, leveraging Ericsson's expansive telecommunications ecosystem.

ERIC

Vonage, Backed By Ericsson, Partners With SAP To Deliver AI-Enhanced Enterprise Workflows And Customer Engagement

AVGO

Broadcom Introduces VeloSky To Drive Network Convergence aAd Enhance Connectivity For Service Providers

<ul>
<li>Ongoing strategic partnership advances joint pipeline in neurodegeneration research</li>
<li>Evotec receives a $20 million payment to further progress research</li>
</ul>

Evotec Advances Neuroscience Partnership With Bristol Myers Squibb, Secures $20M For Neurodegeneration Research

SQNS

Sequans And Coyote Partner To Improve Stolen Vehicle Recovery With Monarch-Powered Nano 2.0 Tracker

Strategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) has announced that it has not sold any shares or bought additional Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) in the week from Feb. 24 to March 2, 2025. The company has also declared a quarterly cash dividend on its preferred stock.
What Happened: According to an SEC filing dated March 3, Strategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) and its subsidiaries currently hold around 499,096 Bitcoins, which were bought for a total of about $33.1 billion. This averages to roughly $66,357 per Bitcoin, including fees and expenses.
The company announced a quarterly cash dividend for its 8.00% Series A perpetual preferred stock, trading under the ticker symbol STRK on The Nasdaq Global Select Market. The dividend, nearly $1.24 per share, will be paid on March 31, to shareholders who are recorded as of the close of business on March 15.
Furthermore, Michael Saylor, co-founder and executive chairman of Strategy, predicted during an interview with CNBC on Monday that the market cap of Bitcoin would surge to $200 trillion. &#8220;Right now we're about $2 trillion in Bitcoin. It's going to $20 trillion, then it's going to $200 trillion, then it's growing 20% a year. And that capital is coming from overseas. It's coming from China, from Russia, from Europe, from Africa, from Asia,&#8221; stated Saylor.
SEE ALSO: <a href="https://www.benzinga.com/tech/25/03/44099748/tim-cook-says-theres-something-in-the-air-new-macbook-air-or-a-surprise-product-launch-on-the-cards">Tim Cook Says &#8216;There&#8217;s Something In The Air&#8217; — New MacBook Air Or A Surprise Product Launch On The Cards?</a>
Why It Matters: On Monday, Strategy&#8217;s shares saw a 12.6% rise <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44073346/mstr-stock-up-nearly-13-in-monday-pre-market-whats-going-on">in the pre-market </a>trading session, following a surge in Bitcoin&#8217;s value. This surge was triggered by President Donald Trump&#8216;s announcement of a U.S. strategic cryptocurrency reserve, wherein the President declared his preference for Bitcoin and Ethereum. The stock also surged after Saylor announced in a post on X that the company&#8217;s Bitcoin investments generated $2.6 billion in profits during the first two months of 2025.
Saylor hailed Trump&#8217;s plan as "a more liberal economic policy," and emphasized that a well-organized digital asset policy would foster economic growth and encourage innovation. 
Despite the pre-market rise, the stock ended 1.77% lower to close at 250.92 on Monday, as per <a href="https://www.benzinga.com/pro/">BenzingaPro</a>. 
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/equities/25/03/44079509/preparing-for-worse-doesnt-mean-dumping-stocks-investing-wisdom-from-market-guru-sam-ro">&#8220;Preparing For Worse Doesn&#8217;t Mean Dumping Stocks&#8221;: Investing Wisdom From Market Guru Sam Ro</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

MSTR

MSTR Retains Bitcoin, Declares Preferred Dividend As Michael Saylor Predicts $200 Trillion Market Cap For Bitcoin

<ul>
<li>Steep Decline in RC Stock Price Following Q4 2024 Earnings Release Has Potential to Erase More Than $30 Million in Value for&nbsp;UDF IV Shareholders Under Proposed Merger</li>
<li>NexPoint Urges Board to Reconsider Hasty Rejection of NexPoint's Proposal and Postpone Special Meeting to Properly Evaluate Transactions on Behalf of Shareholders</li>
</ul>

NXDT

Reported Earlier, NexPoint Asks UDF IV Board To Reconsider Merger After Ready Capital Stock Drops 25%

Bearish investor sentiment as measured by the American Association of Individual Investors reached a high of 60.6%, just before the S&amp;P 500 experienced its worst day of 2025 and second-worst March trading day ever on Monday.
What Happened: As highlighted by Ryan Detrick, the chief market strategist at Carson Research <a href="https://www.carsongroup.com/insights/blog/why-we-expect-some-green-in-march">in</a> his latest note, the bearish sentiment rose more than 60%, for the week ended Feb. 26. This was the seventh highest time in history since the poll was started in 1987.
Additionally, the 60.6% bearish reading was the highest in 30 months since September 2022 and is the third-highest reading over the last 10 years, as highlighted by LPL Financial in their <a href="https://www.lpl.com/research/blog/investor-sentiment-hits-extremely-bearish-levels.html">note</a>.
Detrick observed the historical data and suggested a potential contrarian buying opportunity. He noted that, on average, stocks have risen approximately 28% in the year following periods when bearish sentiment exceeded 60%.
Expanding the analysis to include all instances where bearish sentiment surpassed 55% in the AAII survey, he found consistently strong returns over the subsequent year. However, he cautioned that exceptions exist, highlighting the spike in fear observed in early 2008, which was followed by significantly lower returns a year later.
"Assuming we aren't heading into another financial crisis (we don't think we are), the other times we saw this was quite bullish for investors willing to stay strong and not panic sell. The S&amp;P 500 was up a median of nearly 13% six months later and 18% a year later," he stated.
See Also: <a href="https://www.benzinga.com/25/03/44070799/mark-cuban-supports-trumps-new-gold-card-scheme-if-sold-to-corporations-for-employee-citizenship-have-a-look-at-the-listed-companies-with-most-number-of-immigrants">Mark Cuban Supports Trump&#8217;s New &#8216;Gold Card&#8217; Scheme If Sold To Corporations For Employee Citizenship: Here&#8217;re The Listed-Companies With Most Number Of Immigrants</a>
Why It Matters: The survey data showed that only 19.4% of investors were bullish, whereas 20% had a neutral market sentiment. According to AAII, the bullish sentiment was unusually low and below its historical average of 37.5% for the seventh time in nine weeks.
Contrary to the AAII Sentiment Indicator, which indicates most investors remain bearish on the short-term outlook for stocks, respondents of the BofA survey remain cautiously optimistic, noted George Smith, portfolio strategist at LPL Financial.
"Given that the AAII Sentiment Indicator's bull-bear spread is bearish and respondents of the BofA survey have conflicting views on the likelihood of a global recession and the valuation of U.S. equities, the consensus on markets appears to be relatively neutral," said Smith.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell on Monday. The SPY declined 1.75% to $583.77, and the QQQ dropped 2.19% to $497.05, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44074852/sp-500-correction-overdue-will-the-markets-sideways-dance-turn-into-a-tumble-focus-on-balance-and-diversification-recommends-analyst">S&amp;P 500 Correction &#8216;Overdue:&#8217; Will The Market&#8217;s &#8216;Sideways&#8217; Movement Turn Into A Tumble? &#8216;Focus On Balance And Diversification,&#8217; Says Analyst</a></li>
</ul>
Photo courtesy: Shutterstock

S&P 500 Selloff Spikes Investor Pessimism: Bearish Sentiment Hits 30-Month High, But This Expert Recommends Investors To 'Stay Strong And Not Panic Sell'

Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) sold 7,326 electric vehicles in February in the U.S., marking a growth of 15% from the corresponding period last year, thanks to a jump in sales of its Mustang Mach-E SUV and its E-Transit electric vans which offset a drop in sales of its F-150 Lightning truck.
What Happened: Ford currently sells only three pure electric vehicles in the U.S. 
While Mustang Mach-E sales jumped 13% year-on-year, E-Transit sales rose 111%, offsetting a 15% drop in F-150 Lightning truck sales. 
The Mach-E SUV, a rival to Tesla Inc&#8217;s best-selling Model Y SUV, was the best-selling electric vehicle from Ford last month.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>EV Model</td>
<td>Feb. 2025 Sales</td>
<td>Feb. 2024 Sales</td>
</tr>
<tr>
<td>Mustang Mach-E</td>
<td>3,312</td>
<td>2,930</td>
</tr>
<tr>
<td>F-150 Lightning</td>
<td>2,199</td>
<td>2,578</td>
</tr>
<tr>
<td>E-Transit</td>
<td>1,815</td>
<td>860</td>
</tr>
</tbody>
</table>
</figure>
Overall Ford vehicle sales in the U.S. <a href="https://www.benzinga.com/news/large-cap/25/03/44081963/ford-february-us-sales-slide-8-9-ev-sales-jump-15-details">dropped 9% last month</a>, owing to a steep 13% fall in internal combustion vehicle sales. Hybrid vehicle sales jumped 27.5% in the same period. 
Why It Matters: In February, Ford CEO&nbsp;Jim Farley addressed the possible impact of the proposed&nbsp;<a href="https://www.benzinga.com/tech/25/02/43524700/ford-ceo-jim-farley-says-trumps-proposed-tariffs-on-mexico-canada-will-be-manageable-in-near-term-but-will-have-huge-impact-if-protracted" target="_blank" rel="noreferrer noopener">25% tariffs on imports from Mexico and Canada</a>, which will take effect on Tuesday. While a few weeks of tariffs will be manageable, prolonged tariffs will have a huge impact on the auto industry and mean higher prices for customers, he said.
Farley also called for &#8220;comprehensive&#8221; tariffs that impact Asian automakers including Hyundai, Kia, and Toyota who import their vehicles into the U.S. from countries like Japan or South Korea. 
"…if we're going to have a tariff policy…it better be comprehensive for our industry. We can't just cherry pick one place or the other because this is a bonanza for our import competitors," he added.
Ford&#8217;s <a href="https://www.benzinga.com/tech/25/02/44000938/stellantis-executive-chairman-speaks-out-against-tariffs-on-vehicles-made-in-mexico-canada-real-opportunity-is-4m-cars-that-are-sold-in-america-that-dont-have-any-us-content">Mach-E is manufactured</a> at the company&#8217;s Cuautitlán Stamping and Assembly Plant in Mexico. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44100938/tesla-supercharger-in-littleton-massachusetts-set-on-fire-ev-company-says-no-customers-were-charging">Tesla Supercharger In Littleton, Massachusetts Set On Fire: Elon Musk-Led EV Giant Says No Customers Were Using Them</a></li>
</ul>
Photo courtesy: Shutterstock

Ford's Mustang Mach-E Leads Company's US EV Sales In Feb But Trump Tariffs Threaten Future

In light of potential tariff threats from President Donald Trump, Pfizer Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) CEO Albert Bourla has suggested the possibility of shifting the company&#8217;s overseas manufacturing to its U.S. facilities.
What Happened: At the TD Cowen healthcare conference, Bourla indicated that Pfizer, which already boasts an extensive U.S. manufacturing network, could relocate production to its domestic plants to avoid any potential tariffs, reported Reuters on Monday.
His remarks come as the pharmaceutical industry braces for a possible 25% tariff on imported goods. &#8220;We&nbsp;have the capabilities here (in&nbsp;the U.S.) and the manufacturing&nbsp;sites are operating in good&nbsp;capacity right now. If something&nbsp;happens, we will try to&nbsp;mitigate it by transferring from&nbsp;manufacturing sites outside to the&nbsp;manufacturing sites here,&#8221; Bourla said.
Pfizer has 10 manufacturing facilities and two distribution centers in the United States. 
SEE ALSO:<a href="https://www.benzinga.com/news/25/03/44092335/trumps-tariffs-threaten-canada-mexico-china-and-american-wallets"> </a><a href="https://www.benzinga.com/news/25/03/44092335/trumps-tariffs-threaten-canada-mexico-china-and-american-wallets">Trump&#8217;s Tariffs Threaten Canada, Mexico, China — And American Wallets</a>
Why It Matters: This development follows a&nbsp;<a href="https://www.benzinga.com/markets/25/02/43906811/trump-reportedly-warns-big-pharma-move-manufacturing-to-us-or-face-tariffs">warning</a>&nbsp;from Trump to pharmaceutical companies in February. During a confidential meeting, the President urged drug companies to expedite the transfer of their overseas production to the U.S. or face the possibility of tariffs.
Among the attendees of this meeting were the CEOs of Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and Pfizer, along with the head of the industry's largest lobbying group. The executives aimed to convince Trump to support measures targeting middlemen blamed for increasing out-of-pocket costs and to limit a law allowing the federal government to negotiate specific drug prices.
Though the Trump administration has hinted at possible exemptions to reciprocal tariffs for certain sectors, including pharmaceuticals, a final decision is yet to be made.
While many see reshoring as a potential solution to avoid tariffs, it may not be pragmatic. Independent healthcare analyst Joshua P. Cohen wrote in Forbes, &#8220;..this takes time and is logistically complex.&#8221; He stated that generic products might call for volume purchase guarantees, and a public-private partnership may be required to boost infrastructure and regulatory compliance. &#8220;Whether the Trump administration is prepared to co-invest in a long-term strategy remains to be seen,&#8221; says Cohen.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/general/social-media/25/03/44100560/reddit-co-founder-alexis-ohanian-joins-frank-mccourts-tiktok-bid-amid-competition-from-mrbeast-jesse-tinsley-and-reid-rasner">Reddit Co-Founder Alexis Ohanian Joins Frank McCourt&#8217;s TikTok Bid Amid Competition From MrBeast, Jesse Tinsley, And Reid Rasner</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Pfizer CEO Says Company May Shift Overseas Manufacturing To US Amid Looming Tariff Threats: 'Will The Trump Administration Co-Invest', Asks Analyst

BNY intends to use the net proceeds from the sale of the depositary shares for general corporate purposes, as further described in the preliminary prospectus supplement.
BNY intends to use the net proceeds from the sale of the depositary shares for general corporate purposes, as further described in the preliminary prospectus supplement.

Reported Earlier, BNY Prices $500M Public Offering Of Depositary Shares Linked To 6.300% Series J Preferred Stock, Expected To Close March 10

PTLO

Reported Earlier, Portillo's Engages With Shareholders As Engaged Capital Seeks Board Seats At 2025 Annual Meeting

Humana announced that it has priced a public offering of $1.25 billion in aggregate principal amount of senior notes. These senior notes are comprised of $750 million of the company's 5.550 percent senior notes, due 2035, at 99.885 percent of the principal amount and $500 million of the company's 6.000 percent senior notes, due 2055, at 98.951 percent of the principal amount (collectively, the "Senior Notes Offerings"). The Senior Notes Offerings are expected to close on March 5, 2025, subject to the satisfaction of customary closing conditions.

Reported Earlier, Humana Prices $1.25B Debt Offering, Including $750M 5.550% Senior Notes Due 2035 And $500M 6.000% Senior Notes Due 2055

Smart Sand (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SND#NASDAQ">SND</a>) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.09 by 11.11 percent. This is a 166.67 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $91.40 million which beat the analyst consensus estimate of $65.90 million by 38.69 percent. This is a 47.55 percent increase over sales of $61.95 million the same period last year.

Earnings Beats

Earnings Misses

Smart Sand Q4 2024 GAAP EPS $0.08 Misses $0.09 Estimate, Sales $91.40M Beat $65.90M Estimate

ATCH

Reported Earlier, AtlasClear Reports 800% Market Cap Increase And Strong Subsidiary Performance With 2024 Revenues Exceeding $13.2M

Health Care

Press Releases

Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)

General

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024

Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

Financing

Candel Therapeutics Announces $80 Million Proposed Public Offering

Candel Therapeutics Announces Pricing of Public Offering

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Absci

Akebia Therapeutics

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Astria Therapeutics

aTyr Pharma

Aura Biosciences

Celcuity

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Emergent BioSolutions

Erasca

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Heron Therapeutics

Humacyte

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Oruka Therapeutics

Prime Medicine

PureTech Health plc - American Depositary Shares

PureTech Health

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Sage Therapeutics

Solid Biosciences

Stoke Therapeutics

Savara

Tourmaline Bio

Upstream Bio

Canaccord Genuity

HC Wainwright & Co.

Citigroup

B of A Securities

BMO Capital

Screenshot 2024-06-13 at 5.29.56 PM

Biotech

Candel Therapeutics&#39; (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments

Screenshot 2024-06-06 at 5.30.54 PM

Candel Therapeutics&#39; (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers

Screenshot 2024-05-31 at 5.22.29 PM

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

Screenshot 2024-04-04 at 9.54.11 PM

Chief Science Officer Talks Innovation In Cancer Research

Screenshot 2024-03-25 at 6.13.53 PM

The CEO Of This Innovative BioPharma Is Bringing Light To Cancer Research

Screenshot 2024-03-14 at 5.26.26 PM

Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors

Screenshot 2024-03-05 at 6.31.45 PM

CGON

CLDI

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Screenshot 2024-02-27 at 6.29.08 PM

Moving Fast: Candel&#39;s (NASDAQ: CADL) CAN-3110 Granted FDA Fast Track Designation For Recurrent High-Grade Glioma Following Fast Track Designation For CAN-2409 In Pancreatic Cancer

Comments

Candel Therapeutics

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌